Company Quick10K Filing
Fluidigm
10-Q 2020-03-31 Filed 2020-05-11
10-K 2019-12-31 Filed 2020-02-27
10-Q 2019-09-30 Filed 2019-11-08
10-Q 2019-06-30 Filed 2019-08-07
10-Q 2019-03-31 Filed 2019-05-07
10-K 2018-12-31 Filed 2019-03-18
10-Q 2018-09-30 Filed 2018-11-06
10-Q 2018-06-30 Filed 2018-08-08
10-Q 2018-03-31 Filed 2018-05-08
10-K 2017-12-31 Filed 2018-03-08
10-Q 2017-09-30 Filed 2017-11-07
10-Q 2017-06-30 Filed 2017-08-08
10-Q 2017-03-31 Filed 2017-05-09
10-K 2016-12-31 Filed 2017-03-03
10-Q 2016-09-30 Filed 2016-11-09
10-Q 2016-06-30 Filed 2016-08-09
10-Q 2016-03-31 Filed 2016-05-09
10-K 2015-12-31 Filed 2016-02-29
10-Q 2015-09-30 Filed 2015-11-09
10-Q 2015-06-30 Filed 2015-08-10
10-Q 2015-03-31 Filed 2015-05-11
10-K 2014-12-31 Filed 2015-02-26
10-Q 2014-09-30 Filed 2014-11-06
10-Q 2014-06-30 Filed 2014-08-04
10-Q 2014-03-31 Filed 2014-05-12
10-K 2013-12-31 Filed 2014-03-12
10-Q 2013-09-30 Filed 2013-11-07
10-Q 2013-06-30 Filed 2013-08-07
10-Q 2013-03-31 Filed 2013-05-09
10-K 2012-12-31 Filed 2013-03-12
10-Q 2012-09-30 Filed 2012-11-09
10-Q 2012-06-30 Filed 2012-08-14
10-Q 2012-03-31 Filed 2012-05-15
10-K 2011-12-31 Filed 2012-03-26
10-Q 2011-09-30 Filed 2011-11-14
10-Q 2011-06-30 Filed 2011-08-09
10-Q 2011-03-31 Filed 2011-05-12
10-K 2010-12-31 Filed 2011-03-28
8-K 2020-05-07 Earnings, Exhibits
8-K 2020-05-05 Officers
8-K 2020-04-21 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2020-04-14 Earnings, Exhibits
8-K 2020-03-04 Enter Agreement, Exhibits
8-K 2020-02-10 Earnings, Exhibits
8-K 2020-01-14 Earnings, Exhibits
8-K 2019-11-20 Enter Agreement, Off-BS Arrangement, Sale of Shares, Other Events, Exhibits
8-K 2019-11-05 Earnings, Exhibits
8-K 2019-08-01 Earnings, Exhibits
8-K 2019-07-23 Officers, Exhibits
8-K 2019-06-03 Officers, Shareholder Vote, Exhibits
8-K 2019-05-02 Earnings, Exhibits
8-K 2019-04-18 Officers
8-K 2019-03-20 Enter Agreement
8-K 2019-02-27 Other Events
8-K 2019-02-20 Other Events
8-K 2019-02-13 Other Events
8-K 2019-02-04 Earnings, Officers, Exhibits
8-K 2018-12-11 Other Events, Exhibits
8-K 2018-11-01 Earnings, Exhibits
8-K 2018-10-30 Officers, Exhibits
8-K 2018-09-18 Officers, Exhibits
8-K 2018-08-02 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-08-02 Earnings, Exhibits
8-K 2018-07-30 Officers
8-K 2018-05-31 Shareholder Vote, Regulation FD
8-K 2018-05-03 Earnings, Exhibits
8-K 2018-03-15 Officers
8-K 2018-03-12 Off-BS Arrangement, Sale of Shares, Other Events, Exhibits
8-K 2018-03-06 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-03-02 Other Events, Exhibits
8-K 2018-02-08 Earnings, Exhibits
8-K 2018-02-06 Other Events

Fluidigm Financials

FLDM Metrics, Comps, Filings

Quarterly | Annual

Business

Fluidigm is a global company that improves life through comprehensive health insight. Our innovative technologies and multi-omic tools are used by researchers to reveal meaningful insights into health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. We create, manufacture, and market a range of products and services, including instruments, reagents and software that are used by researchers worldwide.

Our focus is on the most pressing needs in translational and clinical research, including cancer, immunology and immunotherapy. We use proprietary CyTOF® and microfluidics technologies to develop innovative end-to-end solutions that have the flexibility required to meet the needs of translational research and the robustness to support high-impact clinical research studies.

Our mass cytometry Helios™ system deeply profiles cell phenotype and function. Referenced by hundreds of peer-reviewed publications around the world, mass cytometry is setting a new standard in human immune profiling. Transforming biological imaging, our Hyperion™ Imaging System enables highly multiplexed protein biomarker detection in tissues and tumors while still preserving tissue architecture and cellular morphology information using Imaging Mass Cytometry™ (IMC™). Our microfluidic systems complement our mass cytometry offerings by providing highly scalable and automated workflows for quantitative polymerase chain reaction, or PCR, gene expression, copy number variation analysis, and next-generation sequencing library preparation. Used to detect somatic and genomic variations from a range of different sample types, these automated systems provide the cost efficiencies, flexibility and proven analytical performance that customers need to meet the increasing demands of molecular biomarker analysis.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Equity

Income Statement ($BB Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($BB Quarterly)

Ops, Inv, Fin

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Illumina (ILMN) 44,722 69% 35.1 14% 7,089 2,650 3,458 2,395 973 1,255 44,038
Agilent Technologies (A) 24,292 54% 18.0 9% 9,452 4,704 5,163 2,805 877 1,368 24,690
Mettler Toledo (MTD) 17,554 58% 26.5 21% 2,636 2,198 2,983 1,720 550 700 18,558
Waters (WAT) 15,473 18% 31.8 15% 2,561 2,446 2,405 428 392 513 16,324
Bio-Rad Laboratories (BIO) 10,341 55% 12.0 5% 7,177 2,046 2,304 1,259 377 850 10,215
PerkinElmer (PKI) 9,500 48% 25.3 4% 6,489 3,782 2,835 1,374 234 449 11,362
Bruker (BRKR) 6,836 48% 23.2 9% 2,352 1,507 2,026 972 207 305 7,055
Coherent (COHR) 3,296 34% 37.6 3% 2,083 798 1,431 486 54 79 2,977
Accelerate Diagnostics (AXDX) 1,034 45% -15.4 -58% 147 137 8 3 -85 -72 1,112
Pacific Biosciences of California (PACB) 862 33% -7.4 -79% 146 95 82 27 -115 -113 840
Fluidigm (FLDM) 852 40% -16.2 -19% 269 107 117 46 -52 -51 824
Quanterix (QTRX) 607 39% -12.8 -22% 176 39 52 20 -39 -39 501
EyePoint Pharmaceuticals (EYPT) 194 67% -2.9 -101% 79 63 12 8 -80 -72 209
Harvard Bioscience (HBIO) 130 55% 33.8 -1% 163 86 119 66 -2 5 175
HTG Molecular Diagnostics (HTGM) 36 48% 0.2 -29% 51 23 14 7 -15 -13 -2
Precipio (PRPO) 20 4% -2.2 -42% 23 7 6 0 -9 -9 19
Astrotech (ASTC) 11 17% -1.4 -144% 5 4 0 0 -7 -7 10
Bionano Genomics (BNGO) 7 29% 0.1 -81% 19 27 11 3 -16 -13 -1
Aethlon Medical (AEMD) 0 0% 0.1 -579% 1 1 0 0 -7 -7 -0

Balance Sheet ($MM)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash10121481066596232203510144313437242929433632354440615842393695662628
Accounts Receivable109910101113101112111913172220222625201913151414141516171817191914
Inventory566677777881316171617191918201821202019181515151513141415
PP&E3334441755519912132814141434151717401514133411101032888
Assets8683797165117114113112114117425418410408395389378371354342320306292279292287270259252304291284269
Accounts Payable3544333323488766666465444545764785
Long-Term Debt131210300
Liabilities2323221916141313141721257256256257253256254256255258252253254255253256221224230232109111107
Stockholders' Equity6259575249103101100989796167162155150142133124115998468533924393149352272182173163
Income Statement ($MM)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue11111311131316151918212628303327292931292822252624252825262932302826
Cost of Revenue111111111122131312
Gross Profit283028272124242324262425171514
R&D33445444556811131210109101010999787777887
SG&A8889119111112121415221919202120222524212323212016191920232221
Tax00000000000-2-1-1-1-1-0-0-0-1-1-0-2-2-1-10-1-0-10-1-1
Net Income-7-4-3-7-5-4-4-4-4-4-5-15-13-14-11-16-15-9-13-20-19-20-18-17-17-16-10-13-16-15-25-14-13
Cash Flow ($MM)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-2-2-7-4-3-3-1-3-13-110-9-4-10-8-13-4-8-7-13-11-8-8-81-16-4-4-20-5-5
Cash Investing55575-22-28-1210-121-59-4610-718521010141840-4-041-10-367
Cash Financing-1-1-3-154-12112197111410000-0-00-0290-0-2-001-0